Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 9/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 9/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6307454 | 0.98 | TDP1 (0.49) | TDP1POLBCA12CA1CA3 | |
| SCHEMBL10285341 | 0.77 | CA12 (0.48) | CA12CA1CA3CA4CA6 | |
| SCHEMBL30946271 | 0.75 | DAO (0.53) | CA12CA1CA3CA4CA6 | |
| SCHEMBL3874061 | 0.75 | KDM4E (0.60) | CA12CA1CA3CA4CA6 | |
| SCHEMBL29507335 | 0.75 | CYP1A2 (0.62) | TDP1POLBCA12CA9CYP1A2 | |
| SCHEMBL30946262 | 0.75 | CA12 (0.47) | CA12CA1CA3CA4CA6 | |
| SCHEMBL450729 | 0.75 | CYP1A2 (0.62) | TDP1POLBCA12CA9CYP1A2 | |
| SCHEMBL1082903 | 0.75 | DAO (0.53) | CA12CA1CA3CA4CA6 | |
| SCHEMBL433885 | 0.75 | TNKS2 (0.62) | CA12CA1CA3CA4CA6 | |
| SCHEMBL709815 | 0.75 | PDE3B (0.52) | CA12CA1CA3CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3331861-A1 | PROCESS FOR THE PREPARATION OF 5-AMINO-QUINOLIN-2(1H)-ONES AND THEIR TAUTOMER FORMS 5-AMINO-QUINOLIN-2-OLS | Bayer Pharma Aktiengesellschaft (DE) | 2018-06-13 | — | — | EP | claimed |
| WO-2017025371-A1 | PROCESS FOR THE PREPARATION OF 5-AMINO-QUINOLIN-2(1H)-ONES AND THEIR TAUTOMER FORMS 5-AMINO-QUINOLIN-2-OLS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-16 | — | — | WO | claimed |
| US-20220274927-A1 | MEMBRANE-ACTIVE ANTI-BACTERIAL COMPOUNDS AND USES THEREOF | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2022-09-01 | — | — | US | disclosed |
| EP-4021441-A1 | MEMBRANE-ACTIVE ANTI-BACTERIAL COMPOUNDS AND USES THEREOF | Trustees of Dartmouth College (US) | 2022-07-06 | — | — | EP | disclosed |
| WO-2021042046-A1 | MEMBRANE-ACTIVE ANTI-BACTERIAL COMPOUNDS AND USES THEREOF | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2021-03-04 | — | — | WO | disclosed |
| US-RE47047-E1 | 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents | ASTRAZENECA AB (SE) | 2018-09-18 | — | — | US | disclosed |
| EP-3331861-A1 | PROCESS FOR THE PREPARATION OF 5-AMINO-QUINOLIN-2(1H)-ONES AND THEIR TAUTOMER FORMS 5-AMINO-QUINOLIN-2-OLS | Bayer Pharma Aktiengesellschaft (DE) | 2018-06-13 | — | — | EP | disclosed |
| EP-3331861-A1 | PROCESS FOR THE PREPARATION OF 5-AMINO-QUINOLIN-2(1H)-ONES AND THEIR TAUTOMER FORMS 5-AMINO-QUINOLIN-2-OLS | Bayer Pharma Aktiengesellschaft (DE) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017025371-A1 | PROCESS FOR THE PREPARATION OF 5-AMINO-QUINOLIN-2(1H)-ONES AND THEIR TAUTOMER FORMS 5-AMINO-QUINOLIN-2-OLS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017025371-A1 | PROCESS FOR THE PREPARATION OF 5-AMINO-QUINOLIN-2(1H)-ONES AND THEIR TAUTOMER FORMS 5-AMINO-QUINOLIN-2-OLS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-16 | — | — | WO | disclosed |
| EP-1363909-B1 | TRICYCLIC ANDROGEN RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARM INC (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20020183346-A1 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2002-12-05 | — | — | US | disclosed |
| WO-2002066475-A2 | TRICYCLIC ANDROGEN RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-08-29 | — | — | WO | disclosed |
| EP-0489379-B1 | 5-amino-5,6,7,8-tetrahydroquinolines and related compounds, a process for their preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (US) | 1998-07-15 | — | — | EP | disclosed |
| CN-1157611-A | Novel quinolone 5- (N-heterosubstituted amino) antimicrobial agents | PROCTER & GAMBLE (US) | 1997-08-20 | — | — | CN | disclosed |
| US-5646163-A | FOR TREATING OR PREVENTING BACTERIAL INFECTIONS IN HUMANS OR ANIMALS | THE PROCTER & GAMBLE COMPANY (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0757675-A1 | NOVEL QUINOLONE 5-(N-HETEROSUBSTITUTED AMINO) ANTIMICROBIALS | THE PROCTER & GAMBLE COMPANY (US) | 1997-02-12 | — | — | EP | disclosed |
| WO-1995029894-A1 | NOVEL QUINOLONE 5-(N-HETEROSUBSTITUTED AMINO) ANTIMICROBIALS | THE PROCTER & GAMBLE COMPANY (US) | 1995-11-09 | — | — | WO | disclosed |
| EP-0342649-B1 | Improved process for the preparation of 5-amino-7-(substituted amino)-quinoline-3-carboxylic acids | WARNER LAMBERT CO (US) | 1994-11-30 | — | — | EP | disclosed |
| EP-0342649-A2 | Improved process for the preparation of 5-amino-7-(substituted amino)-quinoline-3-carboxylic acids | WARNER-LAMBERT COMPANY (US) | 1989-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183346-A1 | Tricyclic androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | TDP1 4061/4885POLB 3439/4885CA12 2394/4885 |
| US-20220274927-A1 | MEMBRANE-ACTIVE ANTI-BACTERIAL COMPOUNDS AND USES THEREOF | LPO, EPCAM, ANTXR2 | TDP1 3654/4885POLB 1808/4885CA12 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.